Duchenne muscular dystrophy (Duchenne) has been officially added to the Recommended Uniform Screening Panel (RUSP) by the U.S. Department of Health and Human Services (HHS), expanding the list of conditions recommended for newborn screening nationwide. This landmark action significantly improves opportunities for early diagnosis and care for children with Duchenne.
The U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. today approved the addition of Duchenne Muscular Dystrophy (DMD) and Metachromatic Leukodystrophy (MLD) to the Recommended Uniform Screening Panel (RUSP) following scientific review and public comment. Early detection of both conditions allows children to receive FDA-approved therapies at the most effective time, helping to slow disease progression and preserve their quality of life.
“As my uncle has said, ‘although children may be the victims of fate, they will not be the victims of our neglect,’” said Secretary Kennedy. “This action honors that principle. Early screening gives every child a fair chance at timely, effective care, and it delivers families the answers and treatment options they deserve—right when they need them most.”
Read More: Clinical Trials for Duchenne (List of All Researches)
